Miltefosine

Levels of enzymatically active caspase-3 are quantified using the ApoAlert Caspase Fluorescent assay kit. Briefly, 1×10⁶ BC-1 PEL cells are treated with 50 μM Miltefosine, 50 μM Perifosine, or 20 nM NVP-BEZ235, as well as the respective vehicle controls. Cells are harvested and lysed 12 hours later. Equivalent micrograms of cell lysate for all samples are incubated with a fluorogenic caspase-3 substrate (DEVD-AFC). Cleavage of DEVD by caspase-3 releases AFC, the fluorescence of which is measured using a FLUOstar OPTIMA fluorometer, with excitation and emission filter wavelengths set to 400 and 505 nm, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NIH3T3 cells are grown in DMEM supplemented with 10% FCS in a humidified atmosphere of 95% air with 5% CO₂. Cells are plated on 35-mm culture dishes (6-well plates) at 0.5-0.8×10⁵ cells/well. Growth is established for 18-24 h and the cell number of representative wells is determined (time 0). The experiments are started by addition of fresh prepared solution of Miltefosine at given concentrations to the cells or equal volumes of Tris-HCI to control cells. After incubation for 60 h, cells are counted with an electronic counter. Cellular multiplication is calculated^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mice^[3]
PEL cells are washed in ice-cold phosphate buffered saline, counted, and diluted in 100 μL of PBS mixed with 100 μL of growth factor-depleted Matrigel. A total of 1×10⁵ to 7.5×10⁵ BC-1 cells are injected subcutaneously into the right flank of NOD.CB17-Prkdc^scid/J or CB17-Prkdc^scid/J mice. The mice are monitored on alternate days for development of palpable tumors (2 mm³), at which point drug or vehicle treatments are initiated, and are administered either intraperitoneally (Perifosine) or by oral gavage (Rosiglitazone, NVP-BEZ235) 5 days a week. Groups of 5 to 7 mice are used to generate PEL tumors and treated with either vehicle or drug cocktail. Each biologic experiment is repeated multiple times. For Rosiglitazone, 0.25% methylcellulose is used as vehicle, and 30 mg/kg or 60 mg/kg Rosiglitazone is suspended in methylcellulose. For Perifosine and Miltefosine, PBS is used as a vehicle and 50 mg/kg Perifosine or Miltefosine is dissolved in PBS. For NVP-BEZ235, the compound is dissolved in a 1:9 vol/vol mixture of 1-methyl-2-pyrrolidone and polyethylene glycol 300. A dose of 40 mg/kg NVP-BEZ235 or equal volume of the vehicle is administered. Tumor diameters are measured using digital calipers, and tumor volume is calculated. The tumors are excised and fixed in formalin. Statistical analyses are performed using linear model fit by maximum likelihood with individual animals treated as random effect.
Rats^[4]
Male Sprague-Dawley rats (weight 270-290 g) are divided into five groups (n=5). Rats in the treatment groups are administered a single 10 mg/kg oral dose of Miltefosine (MFS) either as an aqueous solution or MFS-LNCs dispersion by gastric gavage. This dose is equivalent to the 20 mg/kg Miltefosine dose administered to mice in the preclinical study after correction for rats. Following administration, blood samples are collected via the orbital plexus under anesthesia at time intervals of 0.5, 1, 2, 4, 7, 10, 24, 48, 72 and 216 h in Eppendorf tubes containing EDTA. Blood samples are then centrifuged immediately at 4000 rpm for 10 min. Plasma samples are frozen and maintained at -80°C pending analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.